MedTrace Logo

A Study of Azacitidine for Patients With Int/High -Risk MDS and AML-MRC

NCT03978364 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-06-07

No results posted yet for this study

Summary

evaluate the clinical efficacy and safety of azacitidine combined with HAG regimen for patients with int/high -risk MDS and AML-MRC with less than 30% blasts compared with azacitidine

Conditions

  • Myelodysplastic Syndromes,Acute Myeloid Leukemia

Interventions

DRUG

Azacitidine combined HHT

Azacitidine 75mg/m2，iH，qd×7days，HHT，3mg/m2 ivdrip qd×3 days

DRUG

Azacitidine regimen

Azacitidine 75mg/m2，iH，qd×7days，28 days a cycle

Sponsors & Collaborators

  • Shandong Provincial Hospital

    lead OTHER_GOV

Principal Investigators

  • Xin Wang, MD, PhD · Department of Hematology, Shandong Provincial Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2022-06-01
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03978364 on ClinicalTrials.gov